Core Viewpoint - The company, Gilead Sciences (歌礼制药), has seen a stock increase of over 4%, currently trading at 11.68 HKD, with a transaction volume of 8.54 million HKD. The company announced the clinical development of two new combination drugs, ASC36 and ASC35, aimed at obesity treatment, with plans to submit an IND application to the FDA by Q2 2026 [1]. Group 1 - Gilead Sciences has entered the clinical development phase for ASC36, a new generation amylin receptor agonist, and ASC35, a new generation GLP-1R/GIPR dual-target agonist combination formulation [1]. - The company anticipates submitting an IND application for ASC36 and ASC35 to the FDA for obesity treatment by the second quarter of 2026 [1]. - The CEO, Dr. Wu Jinzi, expressed optimism about the potential for ASC36 and ASC35 to achieve more significant weight loss effects in obese populations compared to monotherapy, based on encouraging preclinical data [1].
歌礼制药再涨超4% ASC36和ASC35复方制剂进入临床开发阶段